UKPDS研究显示从葡萄糖耐量异常到糖尿病,胰岛β细胞功能按每年8%的速率递减;当血糖升高被诊断为糖尿病时,其胰岛β细胞功能已丧失50%以上[1];而2008年的ADA Banting奖Ralph A Defronzo的研究提示了更可怕的数据,胰岛β细胞衰退的进程比想象的更早,在IGT阶段几乎丧失了80%的β细胞功能[2]。针对2型糖尿病β细胞功能进行性衰退的核心机制,应尽早启用保护胰岛β细胞功能的药物,以改善或延缓胰岛β细胞进行 The UKPDS study showed that, from impaired glucose tolerance to diabetes, islet β-cell function decreases at a rate of 8% per annum; pancreatic β-cell function has been lost more than 50% when hyperglycemia is diagnosed with diabetes mellitus [1]; whereas in 2008 The ADA Banting Award Ralph A Defronzo’s study suggests even more terrible data. The progression of pancreatic beta-cells is earlier than expected and nearly 80% of beta-cell functions are lost during the IGT phase [2]. For the core mechanism of progressive decline of β-cell function in type 2 diabetes, drugs that protect islet β-cell function should be activated as soon as possible to improve or delay islet β-cell